Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease-modifying antirheumatic drugs ...
Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...
Pediatric Rheumatologist Explains Many New Updates to ACR’s Juvenile Idiopathic Arthritis Guidelines
The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side effects in growing children,’ said rheumatologist Susan Shenoi, MS.
A scoping review published in Arthritis Care & Research compares existing recommendations for the use of disease-modifying anti-rheumatic drugs (DMARDs) in pregnancy and reproductive health for women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results